P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
Amit SachdevaRatnabhushan MutyalaNeha MantriShiyun ZhuEdward McNultyMatthew SolomonPublished in: Journal of interventional cardiology (2023)
Among patients with ACS who underwent PCI, we observed a lower risk of all-cause mortality in patients treated with ticagrelor vs clopidogrel, but no difference in other clinical endpoints nor any differences in endpoints between prasugrel vs. clopidogrel users. These results suggest that further study is needed to identify an optimal P2Y12 inhibitor in a real-world population.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery bypass grafting
- coronary artery disease
- atrial fibrillation
- type diabetes
- coronary artery bypass
- skeletal muscle
- ischemia reperfusion injury
- oxidative stress
- blood brain barrier
- subarachnoid hemorrhage
- adipose tissue
- heart failure